39945-50-1

Basic information

• Product Name: 1-CBZ-2-(2-HYDROXY-ETHYL)-PIPERIDINE
• Synonyms: 2-(2-HYDROXY-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;1-CBZ-2-(2-HYDROXY-ETHYL)-PIPERIDINE
• CAS NO: 39945-50-1
• Molecular Formula: C₁₅H₂₁NO₃
• Molecular Weight: 263.33
• Mol File: 39945-50-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 408.7°C at 760 mmHg
• Flash Point: 201°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 2.06E-07mmHg at 25°C
• Refractive Index: 1.544
• CAS DataBase Reference: 1-CBZ-2-(2-HYDROXY-ETHYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CBZ-2-(2-HYDROXY-ETHYL)-PIPERIDINE(39945-50-1)
• EPA Substance Registry System: 1-CBZ-2-(2-HYDROXY-ETHYL)-PIPERIDINE(39945-50-1)

Safety Data

• Hazardous Substances Data: 39945-50-1(Hazardous Substances Data)

Usage

General Description

1-CBZ-2-(2-HYDROXY-ETHYL)-PIPERIDINE is a chemical compound that belongs to the piperidine class of organic compounds. It is a derivative of piperidine with a carboxybenzyl (CBZ) protecting group attached to the nitrogen atom. The molecule also contains a 2-hydroxyethyl group attached to the piperidine ring. 1-CBZ-2-(2-HYDROXY-ETHYL)-PIPERIDINE has potential applications in organic synthesis and pharmaceutical research. It may also be used as a building block in the synthesis of other organic compounds. Additionally, it has properties that make it suitable for use as a reagent in chemical reactions and as a precursor in the synthesis of various pharmaceuticals.

InChI:InChI=1/C15H21NO3/c17-11-9-14-8-4-5-10-16(14)15(18)19-12-13-6-2-1-3-7-13/h1-3,6-7,14,17H,4-5,8-12H2

Upstream product

• 1484-84-0 2(RS)-(2-hydroxyethyl)piperidine 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 

Downstream Products

• 153108-98-6 N-<(benzyloxy)carbonyl>-2-<2-(tert-butyldimethylsiloxy)ethyl>piperidine 
• 190846-24-3 2-(2-Methanesulfonyloxy-ethyl)-piperidine-1-carboxylic Acid Benzyl Ester 
• 441771-92-2 N-[(R)-phenylalanyl]-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 441771-95-5 N-[N-(2,2,2-trichloroethoxycarbonyl)-(R)-cyclohexylalanyl]-2(RS)-[2-(N-t-butoxycarbonyl-4-piperidinyloxy)ethyl]piperidine 
• 441771-98-8 N-[(R)-cyclohexylalanyl]-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 441771-93-3 N-[N-(t-butoxycarbonylmethyl)-(R)-phenylalanyl]-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 190846-42-5 N-(N-cyclohexyl-O-t-butyl-(S)-α-aspartyl)-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 190846-53-8 N-(N-cyclohexylmethyl-O-t-butyl-(S)-α-aspartyl)-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 441771-99-9 N-[N-(t-butoxycarbonylmethyl)-(R)-cyclohexylalanyl]-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 190846-63-0 N-(N-cyclohexyl-N-ethyl-O-t-butyl-(S)-α-aspartyl)-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 441771-97-7 N-[N-(2,2,2-trichloroethoxycarbonyl)-(R)-cyclohexylalanyl]-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 441772-01-6 N-(N-cyclohexyl-N-ethyl-O-t-butyl-(S)-α-aspartyl)-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 441771-91-1 N-[N-(α-fluorenylmethoxycarbonyl)-(R)-phenylalanyl]-2(RS)-{2-[N-(N,N'-di-t-butoxycarbonylamidino)-4-piperidyloxy]ethyl}piperidine 
• 885274-50-0 N-benzyloxycarbonyl-2-(2-oxoethyl)piperidine 

Relevant articles and documents

METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: Synthesis, structure-activity relationships, and pharmacokinetics

The measles virus (MeV), a member of the paramyxovirus family, is an important cause of pediatric morbidity and mortality worldwide. In an effort to provide therapeutic treatments for improved measles management, we previously identified a small, non-nucl

2-substituted piperidines that are ligands for monoamine receptors and transporters

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.